

Children's Tumor Foundation Drug Discovery Initiative Awards

Grantor: Children's Tumor Foundation

Closes: 8/31/2010

Maximum: \$50,000.00

Children's Tumor Foundation Drug Discovery Initiative Awards

The Children's Tumor Foundation Drug Discovery Initiative Awards program supports early stage screening of candidate drug therapies for the treatment of neurofibromatosis (NF): NF1, NF2 and schwannomatosis. Since its launch in June 2006, DDI Awards has funded over 30 studies. These are fuelling the drug pipeline with promising leads; have forged multiple industry collaborations for NF investigators; have resulted in publications; one drug has already advanced to a clinical trial. DDI funding is a catalyst to test new ideas, generate preliminary data then go on to secure larger grants from federal agencies and other sources.

DDI Awards provides up to \$15,000 for in vitro screens and \$30,000 for in vivo screens to test efficacy of candidate NF therapies in cell & animal models. DDI Awards require only a brief (three page) application. If in vitro Awards yield promising data, awardees may apply for subsequent in vivo funding to continue the research.

A limited number of DDI Advanced Awards of up to \$50,000 are available. Only prior recipients of DDI in vivo Awards may apply for DDI Advanced Award. If interested, please contact the Foundation.

There will be two DDI Awards application deadlines in 2010:

February 26, 2010 and August 31, 2010

A critical goal of DDI Awards is to offer rapid review and funding. Most awardees have received funding within 8 weeks of the submission deadline.

Questions? Contact:

Kim Hunter-Schaedle, Ph.D.

Chief Scientific Officer

Children's Tumor Foundation

95 Pine Street, 16th Floor

New York, NY 10005

Tel: 212-344-6633 x 231

Email: khunter-schaedle@ctf.org

Link: <http://www.ctf.org/For-Scientists/Drug-Discovery-Initiative/>

Categories: Chronic Diseases, Disease-Specific Research, Drug Discovery/ Drug Development, Inheritable Disorders, Investigational New Drugs, Novel Therapies, Pharmaceutical Sciences, Pharmacology, Rare Disorders, Tumors

Audience: Allied Health Professional, Pharmaceutical Scientist , Pharmacologist, Physician Researcher